You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. BMX-001 as a Therapeutic Agent for Treatment of High-Grade Gliomas

    SBC: BIOMIMETIX JV LLC            Topic: NCI

    PROJECT SUMMARY/ABSTRACT A randomized, proof-of-concept, Phase 2 clinical trial of a new class of redox-active pharmaceutical is proposed in 160 subjects undergoing primary treatment for high-grade glioma (WHO grade III and IV). Under a prior Phase II SBIR, a Phase 1 clinical trial has been completed with establishment of the recommended dose being used for this Phase 2 clinical trial. This projec ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  2. High-resolution Non-cryogenic Magnetoencephalography: Systems-Level Integration

    SBC: QUSPIN INC.            Topic: NIMH

    Abstract Magnetoencephalography (MEG) is an important functional neuroimaging technique that provides an excellent combination of high spatial and temporal resolution. At present, MEG scanners are handicapped by cost and complexity imposed by cryogenically cooled superconducting sensor technology. In our recently completed Phase II project, we developed new noncryogenic optical sensors that are su ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  3. TITER ON CHIP ALTERNATIVE TO SRID FOR INFLUENZA VACCINE POTENCY DETERMINATION

    SBC: INDEVR, INC.            Topic: NIAID

    DESCRIPTION provided by applicant It is widely acknowledged that for split vaccines potency determination is often a rate limiting step The FDA approved andquot gold standardandquot potency assay for influenza hemagglutinin HA protein based vaccines is single radial immunodiffusion SRID SRID is a time and labor intensive assay often requiring days to complete and a minimum of hou ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. A wearable high-density MEG system with uOPMs

    SBC: FieldLine Inc.            Topic: 101

    Abstract In this Phase II project, we will build a complete high-density wearable full-head MEG system using our micro-OPM sensors and to cross-validate our system against current SQUID-based MEG systems. A complete system consists of (1) the sensor system - an array of 128 sensors and their control electronics that performs synchronous data collection and control; (2) a MEG cap that conforms to t ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  6. Preclinical development of a biological antiviral for universal influenza treatment and prophylaxis using a novel nucleic acid delivery platform

    SBC: SIVEC BIOTECHNOLOGIES, INC.            Topic: NIAID

    The goal of this project is to advance the development of a novel biologic antiviral (SiVEC-IAV™) against human influenza. Influenza is a worldwide public health problem that infects approximately 20% of the U.S. population annually and is associated with an annual economic burden of over $11 billion USD. Although currently available influenza vaccines and antivirals are practical approaches to ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Low Cost Multi-pathogen Laser Diagnostic for HIV and AIDS Co-Infections

    SBC: Precision Photonics Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): Diagnosis and medical management of HIV-infected individuals is significantly enhanced if one can simultaneously define the subset of the most common co-infections for which patients are at risk. Unfortunately, running such a series of parallel diagnostic tests is cost prohibitive, particularly in low-resource settings. Precision Photonics Corporation proposes ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Novel PolC Inhibitor as a Gram-Positive Antibiotic

    SBC: CRESTONE, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The alarming increase in incidence of infections caused by drug-resistant bacteria has created an urgent need for new antibacterial agents. We are developing a novel class of small molecule antibiotics ( TZUs ) targeting PolC, the replicative DNA polymerase in Gram-positive bacteria. These agents exhibit broad-spectrum activity against Gram-positive bacteria, ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Development of radiological/nuclear medical countermeasures to treat Acute Radiation Syndrome (ARS) is a high priority research area for NIAID. Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure, often resulting i death. Granulocyte colony-stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Protecting Pancreatic Islet Grafts from Rejection

    SBC: ISOGENIS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Type 1 diabetes mellitus (DM) is an autoimmune disease that destroys insulin-producing cells of the pancreas. Type 1 DM affects an estimated one million Americans and usually finds its onset in the young. It is one of the leading causes of kidney disease, peripheral neurological diseases and also blindness. It shortens the lifespan primarily through prematur ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government